Multiple Myeloma

The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Latest News

Myeloma cells | Image: ASH image bank
On the Path to Greater Precision in Treating Multiple Myeloma

August 18th 2025

Past efforts to collect data and to understand the relationship between minimal residual disease and outcomes will allow help researchers in multiple myeloma develop a new generation of targeted therapies, decide when treatment can be stopped, and possibly screen populations for the disease.

The model has the potential to boost early detection of MM and contribute to a paradigm shift in the treatment of MM. | Image credit: shidlovski - stock.adobe.com
Model Based on EHR Parameters Can Predict 5-Year Multiple Myeloma Risk

August 13th 2025

Joseph Mikhael, MD | Image: T-GEN
How M-Power Is Building Trust to Raise Awareness of Multiple Myeloma in the Black Community

August 12th 2025

In follow-up PET/CTs, the investigators said those with complete metabolic remissions tended to have superior PFS. | Image credit: Saiful52 - stock.adobe.com
PET/CT Helps Predict Relapse in Patients With Myeloma Undergoing CAR T-Cell Therapy

August 5th 2025

Black, Hispanic, and Pacific Islander patients generally experienced worse OS compared with White patients, while Asian patients had similar outcomes. | Image credit: Colored Lights - stock.adobe.com
Survival Gains in Multiple Myeloma Highlight Progress and Persistent Disparities

July 28th 2025

Experts Weigh in on Multiple Myeloma

Explore the expanding role of bispecific antibody therapies and strategies for managing cytokine release syndrome and infection risks. Dive into real-world data on teclistamab and talquetamab, and uncover new approaches to optimize patient outcomes.

AJMC Insights logo displayed on a blue abstract background with light and dark wave patterns.
Continuing Medical Education
View All
August 19th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 19th 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology
August 19th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer
August 19th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
August 19th 2025

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

1.5 Credits / Hematologic Cancer, Hematology, Oncology

More News

Multiple myeloma
October 14th 2022

Model Predicts Early Disease Progression for Patients With Multiple Myeloma

Rose McNulty
The model was found to be predictive and may help identify patients with multiple myeloma at a high risk of early disease progression.
Multiple myeloma
October 14th 2022

Study Identifies Lenalidomide-Carfilzomib as Best Maintenance Treatment Option in MM

Rose McNulty
Within a selection of therapies showing efficacy over a placebo, lenalidomide-carfilzomib was a standout against the rest of the group.
PCPs Can Pave Way to Faster Diagnosis of Multiple Myeloma
October 10th 2022

PCPs Can Pave Way to Faster Diagnosis of Multiple Myeloma

Jaime Rosenberg
Researchers highlighted the opportunities primary care providers (PCPs) have to promote favorable outcomes through prompt diagnosis as well as help reduce racial disparities in multiple myeloma.
MM survivor
October 6th 2022

Study Evaluates Factors Related to HRQOL in Multiple Myeloma

Mary Caffrey
Regular assessments of patient-reported outcomes (PROs) are important to deliver the best clinical care, including the monitoring health-related quality of life (HRQOL), researchers reported.
Ajay Nooka, MD, MPH, FACP, Winship Cancer Institute
September 16th 2022

Dr Ajay Nooka Discusses Cost Savings and QOL Benefits of MRD-Directed Treatment Decisions

Laura Joszt, MA Skylar Jeremias
Being able to use minimal residual disease (MRD) negativity to make treatment decisions, such as stopping maintenance therapy, can have savings related to cost and quality of life (QOL) for patients, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
picture of blood cells
September 12th 2022

CAR T-Cell Therapy a Story of Opportunities and Challenges in MM

Jared Kaltwasser
Chimeric antigen receptor (CAR) T-cell therapies may help patients with otherwise refractory cases of multiple myeloma, but patients must overcome significant hurdles to access the therapy.
Could CAR-NK Cells Using Cord Blood Offer a Treatment for Multiple Myeloma?
September 9th 2022

Could CAR-NK Cells Using Cord Blood Offer a Treatment for Multiple Myeloma?

Mary Caffrey
For several years, investigators have examined the potential for allogenic natural killer (NK) cells as an alternative for “off-the-shelf” chimeric antigen receptor (CAR) treatments. New study results presented at the International Myeloma Society (IMS) meeting showed CD38 CAR-NK cells significantly reduced the tumor burden—and improved survival
Ajay Nooka, MD, MPH, FACP
September 5th 2022

How Should MRD Results Be Used? Experts Don’t Necessarily Agree, Dr Ajay Nooka Says

Laura Joszt, MA Skylar Jeremias
Everyone agrees that minimal residual disease (MRD) is the best prognostic tool for multiple myeloma, but there is disagreement on how to use the MRD results, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
Ajay Nooka, MD, MPH, FACP
September 2nd 2022

Dr Ajay Nooka Discusses Use of MRD Testing in Multiple Myeloma at Emory

Laura Joszt, MA Skylar Jeremias
Minimal residual disease (MRD) testing is used to understand the depth of response, but currently the data at Emory are not used to make treatment decisions, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
Final Analysis of Phase 2 GRIFFIN Shows Daratumumab Improves PFS After 4 Years
August 27th 2022

Final Analysis of Phase 2 GRIFFIN Shows Daratumumab Improves PFS After 4 Years

Mary Caffrey
Patients receiving the quadruplet therapy have continued to show improved responses and higher rates of minimal residual disease (MRD) negativity.
Image of different skin tones
August 19th 2022

Daratumumab Access Differences Highlight Potential Racial Disparities in MM Care

Maggie L. Shaw
This retrospective chart review investigated outcomes among patients who are White or Black on a daratumumab regimen for multiple myeloma (MM).
Patient filling out form
August 12th 2022

QOL Tool Valuable in Identifying Patients’ Chief Concerns

Julia Bonavitacola
A tool used to identify primary concerns of patients was helpful in identifying main worries about time, as it related to quality of life (QOL), and held value for patients and clinicians.
Topline KarMMa-3 Results for Ide-Cel in Multiple Myleoma Show “Significant Improvement” in PFS
August 10th 2022

Topline KarMMa-3 Results for Ide-Cel in Multiple Myleoma Show “Significant Improvement” in PFS

Mary Caffrey
Ide-cel is a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, which uses the process of genetically modifying a patient’s T cells and infusing them back into the patient to attack the cancer.
x-ray of lungs
August 6th 2022

Rare MM Case Underscores Need to Consider Differential Diagnoses

Maggie L. Shaw
In this case report, a 50-year-old female patient, with a family history of lung cancer, received a diagnosis of multiple myeloma (MM) following presentation with an apical lung mass.
Image of lab research
August 4th 2022

NGF-Based MRD Assessment Demonstrates Potential to Predict MM Disease Progression

Maggie L. Shaw
Previous studies have produced heterogeneous results on next-generation flow (NGF)-based minimal residual disease (MRD) detection, despite improvements to the method’s reproducibility and sensitivity, prompting the present authors to investigate its clinical utility.
myeloma cells
July 28th 2022

Early Use of Novel Therapies in Multiple Myeloma Could Target Bone Marrow Microenvironment

Mary Caffrey
Authors explained how multiple myeloma emerges from earlier clinical phases and the tumor’s microenvironment in the early course of the disease plays a critical role in the survival of myeloma cells.
With Multiple Myeloma, Caregivers May See More Mental Health Effects Than Patients
July 18th 2022

With Multiple Myeloma, Caregivers May See More Mental Health Effects Than Patients

Mary Caffrey
A study in Blood Advances highlights the toll that a terminal diagnosis can have on everyone around a patient.
Survey Finds Shift in Clinician Views of MRD Status in Treatment Decisions for Multiple Myeloma
July 16th 2022

Survey Finds Shift in Clinician Views of MRD Status in Treatment Decisions for Multiple Myeloma

Mary Caffrey
Results looking at acceptance of minimal residual disease (MRD) status found that 60% of participants “would change at least one decision based on an MRD result,” and 54% would use both MRD status and disease risk to make decisions.
Age, Infection, Cardiac Disease Linked to Early Death for Patients With Newly Diagnosed Multiple Myeloma
July 12th 2022

Age, Infection, Cardiac Disease Linked to Early Death for Patients With Newly Diagnosed Multiple Myeloma

Mary Caffrey
Results from a registry study of patients from Australia and New Zealand show that 9.1% of patients with a new diagnosis of multiple myeloma die within a year of diagnosis, and infection contributed to early death in 38% of cases in which a cause of death was reported.
Index Finds Half of MM, CLL Patients in Study Had Financial Difficulty
July 9th 2022

Index Finds Half of MM, CLL Patients in Study Had Financial Difficulty

Mary Caffrey
Financial difficulty during treatment for multiple myeloma (MM) or chronic lymphocytic leukemia (CLL) was associated with lower levels of education, incomes below $60,000, and multiple comorbidities.
picture of hospital
July 2nd 2022

Review of MM Treatment Landscape Compares Clinical Trials With Real-World Results

Rose McNulty
Real-world patients often differ from those eligible for clinical trials, and comparing results in both populations is a key step in fine-tuning treatment strategies for multiple myeloma.
Exploring Genomic and Transcriptomic Changes Throughout Multiple Myeloma Progression
July 1st 2022

Exploring Genomic and Transcriptomic Changes Throughout Multiple Myeloma Progression

Rose McNulty
Whole-exome and RNA sequencing of early and late multiple myeloma tumor samples aimed to provide insight into disease drivers and phenotypes.
Discussing The Future of the RRMM Treatment Landscape
June 28th 2022

Discussing The Future of the RRMM Treatment Landscape

Drs Richter and Kaufman conclude by discussing future promising developments in RRMM therapy.
Improving Payer Education on RRMM Therapy
June 28th 2022

Improving Payer Education on RRMM Therapy

Professional experts offer suggestions on how payers can be further educated on RRMM treatment.
How Do IMiDs Fare In Comparison With Emerging RRMM Treatment Options?
June 28th 2022

How Do IMiDs Fare In Comparison With Emerging RRMM Treatment Options?

Drs Joshua Richter and Jonathan L. Kaufman consider where IMiDs fall in the RRMM treatment landscape in comparison with emerging treatment options, such as bispecific antibodies and CAR T-cell therapy.
Image of test tubes with blood in a lab
June 25th 2022

Interim Phase 2 Trial Results Show Quadruplet Regimen Tolerable, Effective in MM

Rose McNulty
Early results of a multicenter phase 2 trial exploring the efficacy of daratumumab, pomalidomide, dexamethasone, and ixazomib treatment suggest the regimen is safe and effective in relapsed or refractory multiple myeloma (MM).
Ways Institutions Can Support RRMM Treatment Selection
June 21st 2022

Ways Institutions Can Support RRMM Treatment Selection

Two practicing physicians discuss clinical pathways and decision-making tactics used at their respective institutions for RRMM management.
Using Lenalidomide and Pomalidomide in RRMM Management
June 21st 2022

Using Lenalidomide and Pomalidomide in RRMM Management

Dr Richter explains which patients would benefit the most from using lenalidomide vs pomalidomide, while Dr Kaufman calls attention to clinical trials that support the use of pomalidomide in RRMM therapy.
patient speaking with doctor
June 19th 2022

Standard-of-Care Treatments Insufficient in Improving QOL for Patients With Multiple Myeloma

Lindsey Mulrooney
Patients with multiple myeloma frequently relapse and experience deteriorating quality of life, according to findings from the LocoMMotion study, which also reported that specific patient and disease characteristics are associated with poor efficacy outcomes.
nanoparticle image
June 18th 2022

Review Highlights Nanomedicine as Potential Drug Delivery Strategy in Multiple Myeloma

Rose McNulty
A recent review summarized the current knowledge and treatment paradigm of multiple myeloma, including recent advances and challenges in nanomedicine. 
<1
...
5678910111213>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo